Your Good Partner in Biology Research

EGFL7 Antibody

  • 货号:
    CSB-PA890692LA01HU
  • 规格:
    ¥440
  • 促销:
    小规格抗体限时一口价
  • 图片:
    • IHC image of CSB-PA890692LA01HU diluted at 1:300 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
  • 其他:

产品详情

  • 产品名称:
    Rabbit anti-Homo sapiens (Human) EGFL7 Polyclonal antibody
  • Uniprot No.:
    Q9UHF1
  • 基因名:
    EGFL7
  • 别名:
    EGF like domain 7 antibody; EGF like domain containing protein 7 antibody; EGF like domain multiple 7 antibody; EGF-like protein 7 antibody; EGFL 7 antibody; EGFL7 antibody; EGFL7_HUMAN antibody; Epidermal growth factor like domain protein 7 antibody; Epidermal growth factor-like protein 7 antibody; MEGF 7 antibody; MEGF7 antibody; MGC111117 antibody; Multiple EGF like domain protein 7 antibody; Multiple EGF-like domains protein 7 antibody; Multiple epidermal growth factor like domain protein 7 antibody; Multiple epidermal growth factor-like domains protein 7 antibody; NEU1 antibody; NEU1 protein antibody; NOTCH4 like protein antibody; NOTCH4-like protein antibody; RP11 251M1.2 antibody; UNQ187/PRO1449 antibody; Vascular endothelial statin antibody; VE statin antibody; VE-statin antibody; ZNEU 1 antibody; ZNEU1 antibody
  • 宿主:
    Rabbit
  • 反应种属:
    Human
  • 免疫原:
    Recombinant Human Epidermal growth factor-like protein 7 protein (73-198AA)
  • 免疫原种属:
    Homo sapiens (Human)
  • 标记方式:
    Non-conjugated

    本页面中的产品,EGFL7 Antibody (CSB-PA890692LA01HU),的标记方式是Non-conjugated。对于EGFL7 Antibody,我们还提供其他标记。见下表:

    可提供标记
    标记方式 货号 产品名称 应用
    HRP CSB-PA890692LB01HU EGFL7 Antibody, HRP conjugated ELISA
    FITC CSB-PA890692LC01HU EGFL7 Antibody, FITC conjugated
    Biotin CSB-PA890692LD01HU EGFL7 Antibody, Biotin conjugated ELISA
  • 克隆类型:
    Polyclonal
  • 抗体亚型:
    IgG
  • 纯化方式:
    >95%, Protein G purified
  • 浓度:
    It differs from different batches. Please contact us to confirm it.
  • 保存缓冲液:
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
  • 产品提供形式:
    Liquid
  • 应用范围:
    ELISA, IHC
  • 推荐稀释比:
    Application Recommended Dilution
    IHC 1:200-1:500
  • Protocols:
  • 储存条件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 货期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

产品评价

靶点详情

  • 功能:
    Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis.
  • 基因功能参考文献:
    1. Data show that the expression level of epidermal growth factor-like domain 7 (EGFL7) and epidermal growth factor receptor (EGFR) in invasive growth hormone-producing pituitary adenomas (GHPA) was much higher than that of non-invasive GHPA. PMID: 29951953
    2. EGFL7 was found to be a potential predictor for HCC survival and metastasis state. PMID: 29970668
    3. Levels of both EGFL7 mRNA and EGFL7 protein are increased in blasts of patients with acute myeloid leukemia (AML) compared with normal bone marrow cells. High EGFL7 mRNA expression associates with lower complete remission rates, and shorter event-free and overall survival in older (age >/=60 y) and younger (age <60 y) patients with cytogenetically normal AML. PMID: 28533390
    4. In conclusion, miR-126 could inhibit tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression PMID: 27611944
    5. This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6 (mFOLFOX6) (folinic acid, 5-fluorouracil, and oxaliplatin) bevacizumab in patients with previously untreated metastatic colorectal cancer PMID: 28275117
    6. Oncogenic activation of EGFRwt in GBM is likely maintained by a continuous EGFL7 autocrine flow line. PMID: 27725228
    7. Egfl7 is thus an endogenous and constitutive repressor of blood vessel endothelial cell activation in normal and inflammatory conditions and participates in a loop of regulation of activation of these cells by pro-inflammatory cytokines. PMID: 27650497
    8. Up-regulated MALAT1 promoted the invasion and metastasis of GC, and the increase of EGFL7 expression was a potential mechanism via altering its H3 histone acetylation level PMID: 27259812
    9. These findings suggest that the stimulating effect of EGFL7-ESCs on fibroblast proliferation and migration may provide a useful strategy for wound healing. PMID: 27766530
    10. A gene expression study was conducted to investigate the levels of Egfl7 and miRNA126-5p in human carotid artery atherosclerotic plaques PMID: 26799121
    11. By regulating endothelial cell adhesion, EGFL7 plays a key role in the regulation of glioma angiogenesis. PMID: 26722408
    12. The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF, suggests a possible important role of this angiogenic factor in a later oncogenic and infiltrative/metastatic phase. PMID: 26542361
    13. EGFR mutational analysis is useful in the diagnosis of non-small-cell-lung cancer. PMID: 26288231
    14. The aim of the present descriptive study was to analyse the intra-tumoural expressions of epidermal growth factor-like domain 7 (EGFL7) and microRNA-126 (miRNA-126) in primary tumours from patients with stage II-IV colorectal cancer. PMID: 25592646
    15. EGFL7, OPN, and PGE2 may have a role in recurrence and metastasis of hepatocellular carcinoma PMID: 25730089
    16. High EGFL7 expression promotes migration and Epithelial-Mesenchymal Transition in pancreatic Cancer. PMID: 25987088
    17. Loss of EGFL7 expression is associated with Malignant Pleural Mesothelioma. PMID: 26504055
    18. Data suggest that, in trophoblast cells, EGFL7 regulates cell migration and invasion/placentation by activating multiple signaling pathways via MAPK, PI3K (phosphatidylinositol 3-kinase), and NOTCH1 (translocation-associated notch protein 1). PMID: 25667199
    19. EGFL7 may predict response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer PMID: 25140000
    20. Endothelial cells control pancreatic cell fate at defined stages through EGFL7 signaling. PMID: 25601205
    21. EGFL7 enhances EGFR-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PMID: 24945379
    22. demonstrate significantly reduced Egfl7 expression in pre-eclampsia placentas, concurrent with a downregulation of Notch target genes PMID: 24751645
    23. The loss of EGFL7 expression play a role in the development and progression of systemic sclerosis. PMID: 24286167
    24. egfl7 is initially expressed in all endothelial cells and then is progressively restricted to veins and to their neighbouring capillaries. PMID: 24595089
    25. EGFL7 promotes growth of Renal cell carcinoma by facilitating migration and tube formation of endothelial cells. These effects were produced by EGFL7-mediated focal adhesion kinase phosphorylation through combination with epidermal growth factor receptor. PMID: 24815445
    26. malignant glioma cells and glioma vascular endothelial cells highly express VE-statin/Egfl7, which is significantly correlated with the degree of malignancy. PMID: 24696719
    27. Egfl7 is significantly upregulated in human epithelial tumor tissues, suggesting Egfl7 to be a potential biomarker for human epithelial tumors, especially liver and breast cancer. PMID: 23558933
    28. study provides clinical data indicating a relationship between miRNA-126 and the clinical outcome of metastatic colorectal cancer patients treated with chemotherapy combined with anti-VEGF-A, whereas the impact of EGFL7 is more speculative PMID: 23922111
    29. Early-onset intrauterine growth restriction at 20-24 weeks' gestation is associated with higher values of EGFL7 expression in maternal plasma. PMID: 23280513
    30. Egfl7 expression is thus associated with better prognosis factors and with the absence of lymph node invasion in human breast cancer lesions. PMID: 23404186
    31. Data indicate that EGFL7 and integrin alphavbeta3 integrin colocalized in vesicular structures in uman umbilical vein endothelial cells (HUVECs). PMID: 23386126
    32. Two angiogenesis-associated transcripts (Egfl7 and Acvrl1) showed lower expression in early-onset PE versus late-onset pre-eclampsia and versus gestational age-matched controls. PMID: 22013081
    33. Human breast cancer lesions expressing high levels of Egfl7. PMID: 22037871
    34. Studies indicate that Egfl7 controls blood vessel development by promoting endothelial cell migration and proliferation. PMID: 22160377
    35. Heterogeneous methylation in the promoter region of EGFL7 was associated with cancer progression in non-small cell lung cancer. PMID: 22018271
    36. miR-126 can downregulate EGFL7 expression at the protein level in ECV-304 cells. PMID: 20423846
    37. Studies indicate that two biologically active miRNAs miR-126 and its complement miR-126*, which are encoded by intron 7 of the egfl7 gene, have been described to mediate vascular functions. PMID: 20953557
    38. EGFL7 may be used as a predictive marker for glioma prognosis and as a potential therapeutic target for malignant glioma. PMID: 20213100
    39. Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells. PMID: 20837907
    40. miR-126 can inhibit proliferation of non-small cell lung cancer cells through one of its targets, EGFL7. PMID: 20034472
    41. is the first identified inhibitor of mural cell migration specifically produced by endothelial cells. PMID: 14592969
    42. Human EGFL7 may protect endothelial cell from hyperoxia-induced apoptosis by inhibition of mitochondria-dependent apoptosis pathway. PMID: 17934064
    43. Intronic miRNAs from tissue-specific transcripts, or their natural absence, make cardinal contributions to cellular gene expression and phenotype. PMID: 18193184
    44. The lack of association between expression of miRNA and its host gene EGFL7 suggests their regulation by independent stimuli in colon cancer. PMID: 18521848
    45. Mature miR-126 can be generated from three different transcripts of EGFL7 with each one having its own promoter. PMID: 19116145
    46. Egfl7 promotes metastasis of hepatocellular carcinoma (HCC) by enhancing cell motility through EGFR-dependent FAK phosphorylation. PMID: 19824075

    显示更多

    收起更多

  • 亚细胞定位:
    Secreted, extracellular space.
  • 数据库链接:

    HGNC: 20594

    OMIM: 608582

    KEGG: hsa:51162

    STRING: 9606.ENSP00000307843

    UniGene: Hs.91481